Summary To evaluate the natural history of a disease and the effects of therapeutic interventions, it is important to determine which are the causes of treatment failure and to assess the extent to which each cause contributes to the total failure rate. The paper presents a new biostatistical technique to decompose the total event-free survival of a diseased population into cause-specific failure rates. The (Gelman et al., 1990; Castiglione et al., 1990; Kramar et al., 1987 Kramar et al., , 1990 
node-negative postmenopausal patients the incidence of recurrences from breast cancer were found to be no greater than other types of events. This observation highlights the significance of the effect of different adjuvant therapies not only on the disease itself but also on the risk of second primary malignancies and other intercurrent diseases. In general, it was found that the conventional statistical methods tended to overestimate the event-specific rates. In conclusion, the method based on competing risks permits an unbiased analysis of all types of events determining the total event-free survival. It is thus useful for the description of the natural history of breast cancer as well as other diseases.
Adjuvant treatments in early breast cancer have been widely evaluated in randomised trials in the last years. The two most commonly used endpoints are overall survival and relapsefree survival which includes local recurrence, distant metastasis or death as endpoints. Kaplan-Meier and actuarial methods for estimating local recurrence or distant metastasis rates has been frequently used to analyse patterns of failure separately for each failure type. Recently, this procedure has been criticised for possible biases in the estimation of event rates (Gelman et al., 1990) . The most important criticism is that different failure types are assumed independent. Moreover, recurrences are usually emphasised in assessing adjuvant treatments and other tumour events such as new primary malignancies or contralateral breast cancer are often ignored. A more appropriate solution to estimate event rates whatever the type is to evaluate cumulative incidence functions by taking into account other events within a competing risk framework (Gelman et al., 1990; Castiglione et al., 1990; Kramar et al., 1987 Kramar et al., , 1990 .
The purpose of this paper is to report results in terms of event-free survival, obtained in 2,850 patients with early breast cancer included in two randomised trials of adjuvant treatment, using a competing risk approach to estimate probabilities of local recurrences, distant metastases, contralateral breast cancers, other new primary malignancies and deaths unrelated to cancer. Event-specific cumulative rates were estimated by cumulative incidence functions (Kalbfleisch & Prentice, 1980) Preliminary results Details of the adjuvant trials and preliminary results were published previously (Rutqvist et al., 1987 . Results in terms of overall survival and relapse-free survival did not show a significant difference between the chemotherapy and the radiotherapy groups, but radiotherapy in postmenopausal patients and chemotherapy in premenopausal patients tended to be more effective. In the tamoxifen trial, a significant effect was shown in terms of recurrence reduction but there was only a minor difference in overall survival. Detailed analyses on treatment effects assuming competing risks will be published separately.
Patients included in the trials were followed regularly in the oncologic clinics of the Stockholm region according to the following planned schedule: every 3 months in the first 2 years, every 6 months between 2 and 5 years and yearly after 5 years. Examinations included clinical examination and yearly mammograms, other examinations being requested only in case of symptoms.
Registration of second cancers As previously reported (Fornander et al., 1989) EFS curves were estimated using the Kaplan-Meier method (Kaplan et al., 1958) . Differences between the three risk groups were compared using the logrank test (Peto et al., 1977) . assumes independence between the event of interest and death and censoring just as the usual Kaplan-Meier estimate assumes independence between death and censoring in survival studies. When a particular patient can experience more than one event type, this method is not really a decomposition of time to first event since obviously more events are being analysed.
Censor method Another possible method in decomposing event-free survival consists in censoring all events other than the event of interest at the time of their occurrence. Patients are no longer considered at risk of a specific event once any other event has occurred first. In this case, the incidence estimates obtained by the Kaplan-Meier method are made by mixing all events other than the one of interest with truly censored observations. Since event times are censored at the occurrence of other events, this method makes strong assumptions of independence between all event types. Also, the sum of each individual estimate of incidence does not add up to the overall event rate (Appendix).
Include method A third and more appropriate approach to decompose event-free survival consists in including all events defining relapse by using cumulative incidence functions. These incidence estimates subdivide into separate components which add up to the overall ER. No assumption of independence is necessary. In this context, events are considered as competing risks and the appearance of one type of event does not censor the appearance of another. The inadequacies of usual methods of estimation have been pointed out in a recent article (Gelman et al., 1990 ) and a worked example has been provided (Kramar et al., 1990 ).
Usual methods tend to overestimate specific event rates when more than one event type is considered. Event rates when estimated by a competing risk approach reduces biases related to: (i) the assumption of independence between the occurrence of local recurrence and distant metastasis; (ii) exclusion of other events such as new primary malignancy, contralateral breast cancer and intercurrent death in the determination of the event-free survival; (iii) the fact that a new primary malignancy may be incorrectly diagnosed as a metastasis after distant recurrence. Event-specific cumulative incidence curves were thus estimated from the decomposition of the EFS curves and a computer program (COMPETE) developed at the Institut Gustave-Roussy was used for the calculations.
Results obtained using the competing risk approach were compared to the method of ignoring or censoring other events for the data provided here.
Results
The EFS curves for the three groups are shown in Figure 1 . The difference in EFS between the low risk group and both high risk groups was highly significant (P<0.0001).
The subdivision by type of event using the competing risk approach are shown in Figures 2a, b and c, and ten-year estimates are given in the first column of Tables IIIa, b and c for each risk group respectively. The separate estimates in column 1 add up to the total 10 year total event rate of 56.1%, 61.8% and 37.4%, respectively, the complementary value being the EFS.
Local recurrence and distant metastasis rates were, as expected, significantly lower in the low risk postmenopausal group (P<0.0001). The incidence of new primary malignancies was significantly higher in both groups of postmenopausal patients (P = 0.05).
The patterns of failure obtained by using the competing risk approach in the three risk groups were found to be quite different. In the high risk premenopausal group, the 10-year event rates were 34% for distant metastases, 14% for local recurrence and 3% for new primary malignancies (Table  IIIa) . In the high risk postmenopausal group the incidence of distant and local recurrence was similar (Table IlIb) incidence of new primary malignancies was twice as high when compared to the high risk premenopausal group. In the low risk postmenopausal group the risk of new primary malignancies (6% at 10 years) was similar to that observed in the high-risk postmenopausal group, and only 10% of local recurrence and 11% of distant metastasis were observed (Table IlIc) . The incidence of contralateral breast cancer was approximately 5% at 10 years in all three groups.
These results were compared to methods which censor or ignore other events. With the censoring method (column 2), it makes no sense to add the event rates since these estimates do not have a probability interpretation. They are systematically greater than the estimates obtained under the competing risk approach. Also they were obtained by assuming independence between each event type (Appendix). It can easily be verified that the product of one minus these rates is equal to the ER rate in the absence of no ties in the event times. For example, in the high risk premenopausal patients it can be verified that (1 -0.164) x (1 -0.394) x (1 -0.074) x (1 -0.049) x (1 -0.017) is equal to 0.439, the event-free survival rate (Table IIIa) . These estimates can be considered as incidence estimates if one is willing to make strong assumption of independence between all of the event types. The estimates in the third column were obtained by ignoring other events. Patients were considered at risk of each specific event during the whole follow-up time whether or not any other event occurred. This approach is not an appropriate method when the interest is in evaluating which events are contributing to site of first failure. It may give an indication of the incidence of an overall metastasis rate whether or not a local recurrence occurred before and/or afterwards.
More detailed results are shown in Figure 3a , b and c for 1,335 high risk pre-and postmenopausal patients in terms of local recurrence, distant metastasis and second malignancies, respectively, comparing in each figure the results of ignore, censor and include methods. Figure 3a and b show that ignore and censor methods overestimate the probability of distant metastases and local recurrences, this overestimation is greater for the ignore method. For second malignancy (Figure 3c ), defined as contralateral breast cancer or other new primaries, a similar overestimation is observed, but the ignore and censor methods give similar estimations indicating that in most cases this event is the first site of failure. Details on the calculation of local recurrence rates are provided as a worked example in the Appendix for the same category of patients. ing that all other event type had been eliminated (usually referred to as net estimates). The disadvantage of censoring events other than the one of interest is that strong independence assumptions are formulated between each event type (Tables III, column 2) (Gelman et al., 1990) . procedure, the addition of each individual event rate will not equal the total event rate. However, in the case of no ties in the data and because of independence between event types, the product of one minus these estimates should correspond to the overall EFS rate. The comparison of the three methods showed that the event rate estimates obtained by ignoring competing risks can be highly inaccurate, especially for the high risk groups where the inaccuracy in the 10-year rates was greater than 5% (Figure 3) . In cohort studies these rates can be used to estimate the number of cases developing a particular event within a specified time. The ignore method would be more appropriate in this case, since this method provides an estimate for the overall event rate and not just the rate of occurrence of the first event.
When we assumed competing risks among low risk patients, the 10-year total rate of contralateral breast cancer, new primary malignancy and intercurrent death was as high as the total rate or recurrence, approximately 20% ( Figure  2a) . The former events are often ignored when reporting treatment results. However, because of their relative frequency, half of all events, they can significantly influence the EFS. In high-risk patients, local and distant recurrences represented approximately 80% of all events determining EFS and distant metastases were twice as frequent as local recurrences. On the other hand, in low-risk patients local recurrences were as frequent as distant metastases. The observation that the incidence of recurrences from breast cancer were no greater than the incidence of other types of events among the postmenopausal low-risk patients highlights the significance of the effect of different adjuvant therapies on the risk of second primary malignancies and other intercurrent diseases. Such effects -be they beneficial or detrimental -may prove to be as important or even more important for the long-term outcome than the expected treatment benefit in terms of reduction of breast cancer recurrences.
A high incidence of events other than local or distant recurrence can also be of relevance in sample size calculations because the treatment effect on recurrence will be diluted in low-risk patients and it would therefore be appropriate to take into account the other event rates in the calculation of sample size.
The estimation of cumulative incidence rates in the presence of competing risks has not yet been widely applied in the literature, as specific statistical packages are not widely available. In previous studies we have shown that using conventional methods the incidence of specific events can be overestimated and their relative importance can be overshadowed, such as new primary malignancies in early breast cancer (Arriagada et al., 1991) or local failure in limited small cell lung cancer (Arriagada et al., 1992) . A wider use of competing risk analyses will permit to evaluate to what extent such estimates will differ from those provided by conventional methods.
In conclusion, the competing risk approach permits an analysis of all events simultaneously intervening in the determination of EFS and a more accurate definition of patterns of first failure. This methodology in conjunction with conventional methods offers a valuable tool in the description of the natural history of early breast cancer and of possible treatment effects depending on the differences observed. (Kalbfleisch & Prentice, 1980) :
and the cumulative incidence of local recurrence is given by the sum of these individual incidence estimates in all previous time intervals: It can be shown after a few mathematical steps that when cumulative incidence estimates are obtained in this way for each specific event type, then the overall event-free incidence at time x decomposes into a sum of the individual cumulative incidence functions for each event type.
Example
The following table provides a summary of event types occurring in the 1335 high risk pre-and postmenopausal patients. Numerical calculations are only provided for the censor and include methods.
The data are grouped into intervals for the purposes of comparison. The estimates are Kaplan-Meier estimates. In this case, true censored observation in a specific interval are considered at risk of any event for the entire interval. The graphs presented in Figure 3 however, take into account the actual observed event times. 
